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We currently run phase I studies of subcutaneous vaccina-
tions with synthetic peptides for glioma-associated antigen
(GAA) epitopes emulsified in Montanide-ISA-51 and
intramuscular administration of poly-ICLC in HLA-A2+
adult and pediatric patients with gliomas. Primary end-
points were safety and CD8+ T-cell responses against vac-
cine-targeted GAAs: IL-13Ra2, EphA2, Survivin and WT1
(WT1 in adults only). Adults with WHO grade 2 low-
grade glioma (LGG) have an extremely high risk for trans-
formation to high-grade glioma (HGG), and most patients
eventually die of the disease. Because patients with LGGs
may not be as immuno-compromised as patients with
HGG, they may exhibit greater immunological response to
and benefit from the vaccines. We conducted a phase
I vaccine study with: newly diagnosed high-risk LGG with-
out prior radiation therapy (RT) (Cohort 1); newly
diagnosed high-risk LGG with prior RT (Cohort 2); or
recurrent LGG (Cohort 3). Cohorts 1, 2, and 3 have
enrolled 12, 1, and 10 patients, respectively. No regimen-
limiting toxicity has been encountered except for one case
with Grade 3 fever (Cohort 1). Cohort 1 patients demon-
strated significantly higher magnitude of IFN-g ELISPOT
responses than Cohort 3 patients for all 4 GAA epitopes,
suggesting that newly diagnosed patients may have better
vaccine-responsiveness than recurrent patients. The mag-
nitude of the IFN-g ELISPOT responses in this study is
significantly higher than that observed in our previous
phase I/II study in HGG patients. Median progression-free
survival (PFS) periods are 21 months (Cohort 1; range
10-44) and 12 months (Cohort 3; range 3-28). In Cohort
1, 3 patients are still progression-free (32, 33 and 44
months to date). The only patient with large astrocytoma
in Cohort 2 has been progression-free for over 54 months
since diagnosis. There was a positive trend for IFN-g
ELISPOT responses and PFS. Diffuse brainstem gliomas
(BSGs) and other HGGs of childhood carry a dismal prog-
nosis. To date, 24 children were enrolled, 14 with newly
diagnosed BSG treated with RT, and 10 with newly diag-
nosed BSG or HGG treated with RT and concurrent
chemotherapy. No dose-limiting non-CNS toxicity was
encountered. Five children had symptomatic pseudo-
progression, which responded to corticosteroids and was
associated with prolonged survival. Nineteen had stable
disease for > 2 cycles, 2 had partial responses, and 1 had
prolonged disease-free status after surgery. Median survi-
val among the BSG cohort exceeded 13 months. ELISPOT
analysis in 15 children showed GAA responses in 12, to
IL-13Ra2 in 9, EphA2 in 7, and survivin in 7. Careful
monitoring and management of pseudoprogression is
warranted.
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